SGA Advisor Angela Rausch and the students from Lecanto High School will once again bring holiday cheer to the Citrus ...

Shares of US clinical-stage biotech Kymera Therapeutic leapt almost 33% to $88.48 pre-market, as it announced compelling early results for its first-in-class oral STAT 6 degrade KT-621.

Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall ...

This school has produced some of the key figures in the business, science, and entertainment industries today. Find out which ...

Ascentage Pharma (AAPG) Group announced that it presented the latest results from a Phase Ib/II study of Lisaftoclax, a key investigational drug ...

Salut, has set minimum services for the strike. These services will be 100% in the case of urgent or critical hospital ...

Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm US cohort of phase III CELESTIMO study1Data ...

ORLANDO -- For triple-class exposed relapsed or refractory multiple myeloma with extramedullary disease (EMD), a combination of talquetamab (Talvey) and teclistamab (Tecvayli) achieved high response ...

The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data highlighting the potential of Lunsumio® (mosunetuzumab-axgb) in earlier treatment lines for people living ...

AsymBio, a technology-driven global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), today announced the official start ...

The tribunal held that the resolution plan was invalid because several valuable properties were omitted from the Information Memorandum. The ruling emphasises that all assets must be valued and ...